Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial

BACKGROUND: OH2 is a genetically engineered oncolytic herpes simplex virus type 2 designed to selectively amplify in tumor cells and express granulocyte-macrophage colony-stimulating factor to enhance antitumor immune responses. We investigated the safety, tolerability and antitumor activity of OH2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bo, Huang, Jing, Tang, Jialin, Hu, Sheng, Luo, Suxia, Luo, Zhiguo, Zhou, Fuxiang, Tan, Shiyun, Ying, Jieer, Chang, Qing, Zhang, Rui, Geng, Chengyun, Wu, Dawei, Gu, Xiangyong, Liu, Binlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043042/
https://www.ncbi.nlm.nih.gov/pubmed/33837053
http://dx.doi.org/10.1136/jitc-2020-002224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043042/
https://www.ncbi.nlm.nih.gov/pubmed/33837053
http://dx.doi.org/10.1136/jitc-2020-002224

Ejemplares similares